The global migraine drugs market size was valued at USD 1.7 billion in 2017 and is expected to exhibit a CAGR of 18.0% during the forecast period. Increased uptake of novel drug classes, launch of Calcitonin gene-related peptide (CGRP)-based therapies, and high unmet needs are some of the key factors driving market growth.